These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 10352214)
1. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project. Bailie GR; Frankenfield DL; Prowant BF; McClellan W; Rocco MV Am J Kidney Dis; 1999 Jun; 33(6):1187-9. PubMed ID: 10352214 [TBL] [Abstract][Full Text] [Related]
2. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project. Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035 [TBL] [Abstract][Full Text] [Related]
3. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients. Owen WF; Szczech L; Johnson C; Frankenfield D Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369 [TBL] [Abstract][Full Text] [Related]
4. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN. Johnson CA; Rosowski E; Zimmerman SW Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844 [TBL] [Abstract][Full Text] [Related]
5. [Iron deficiency is a common cause of bad response to epoetin treatment. It's important to follow iron status--not only the Hb value]. Wallerstedt SM; Ljungman S; Broms E; Andrén L Lakartidningen; 2005 Sep 12-18; 102(37):2550-1, 2553-5. PubMed ID: 16200900 [TBL] [Abstract][Full Text] [Related]
6. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376 [TBL] [Abstract][Full Text] [Related]
7. Current management of anemia in adult hemodialysis patients with end-stage renal disease. Frankenfield DL; Johnson CA Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409 [TBL] [Abstract][Full Text] [Related]
8. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group. Nissenson AR Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075 [TBL] [Abstract][Full Text] [Related]
9. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis. Abbas EE; Afioni N; Al Wakeel J; Bakr MA; Dham R; Donia A; Droubi N; Khidir E; Mathew CM; Mitwali AH; Naga S; Pingle A; Rashed A; Roshdy A; Shaheen F; Shaibani B; Shaibani FM; Shaker DS; Sheiban A; Solieman M Transplant Proc; 2004; 36(6):1805-11. PubMed ID: 15350482 [TBL] [Abstract][Full Text] [Related]
10. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
11. Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients. Johnson CA; Wakeen M; Taylor CA; Zimmerman SW; Burkart J; Bhattacharya A; Kosorok MR Perit Dial Int; 1999; 19(6):578-82. PubMed ID: 10641779 [TBL] [Abstract][Full Text] [Related]
12. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. Ifudu O; Feldman J; Friedman EA N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143 [TBL] [Abstract][Full Text] [Related]
13. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration. Pussell BA; Walker R Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R; Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642 [TBL] [Abstract][Full Text] [Related]
15. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. Leikis MJ; Kent AB; Becker GJ; McMahon LP Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176 [TBL] [Abstract][Full Text] [Related]
16. A comprehensive vision for intravenous iron therapy. Coyne DW Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257 [TBL] [Abstract][Full Text] [Related]
17. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey. Linde T; Furuland H; Wikström B Scand J Urol Nephrol; 2005; 39(4):329-33. PubMed ID: 16118109 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease. Moran LJ; Carey P; Johnson CA Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988 [TBL] [Abstract][Full Text] [Related]
19. Trends in anemia management among US hemodialysis patients. Coladonato JA; Frankenfield DL; Reddan DN; Klassen PS; Szczech LA; Johnson CA; Owen WF J Am Soc Nephrol; 2002 May; 13(5):1288-95. PubMed ID: 11961017 [TBL] [Abstract][Full Text] [Related]
20. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients. Ahsan N Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]